A combination of the identified 3 genes in BM+ and 8 genes in BM showed better prediction than did each individual gene, and this combination can be used as a training set.
Aim:A high expression of epidermal growth factor receptor (EGFR) is found in most human epithelial tumors, including nasopharyngeal carcinomas (NPC). The overexpression of EGFR has been shown to play an influential role in tumorigenesis and the progression of malignant tumors. Therefore, blocking EGFR might be a potential targeted treatment for NPC. Nimotuzumab is an anti-EGFR monoclonal antibody that exhibits remarkable anti-proliferative, anti-angiogenic, and pro-apoptotic effects. Methods: Here we report five patients with loco-regionally advanced NPC, treated with nimotuzumab 100 mg i.v./week for 8 weeks in combination with radiotherapy in a total dose of 70-74 Gy. Results: A computed tomography evaluation of all five patients showed that the primary tumor volume was reduced, ranging from 64.1 to 98% and the nodal volume was reduced by 90.7-100%. No severe adverse events related to nimotuzumab were observed. Conclusion: The use of nimotuzumab in combination with radiotherapy was potentially beneficial and safe for patients with advanced NPC.
There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.